Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Add To Watchlist

Recent & Breaking News (NDAQ:EXEL)

Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting

Business Wire April 26, 2018

Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018

Business Wire April 11, 2018

Exelixis Elects Dr. Maria Freire to Its Board of Directors

Business Wire April 9, 2018

Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma

Business Wire March 28, 2018

New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire October 6, 2017

Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORγt Inverse Agonist Program

Business Wire October 4, 2017

Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study

Business Wire September 24, 2017

12 Biggest Mid-Day Losers For Friday

Benzinga.com September 22, 2017

Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25

Business Wire September 19, 2017

Watch These 5 Huge Call Purchases In Monday Trade

Benzinga.com September 11, 2017

Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

Business Wire September 9, 2017

Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy

Business Wire September 7, 2017

Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress

Business Wire September 6, 2017

Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13

Business Wire August 29, 2017

Stock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma, and Intra Cellular Therapies

PR Newswire August 28, 2017

A Peek Into The Markets: U.S. Stock Futures Rise; All Eyes On Fed Minutes

Benzinga.com August 16, 2017

Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer

Business Wire August 16, 2017

Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Business Wire August 2, 2017

Investor Network: Exelixis, Inc. to Host Earnings Call

Accesswire August 2, 2017

Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress

Business Wire August 1, 2017